Mutations in Chromatin Regulator Genes Associate With TMB and Immunotherapy Response in Melanoma
- 24 October 2026
- journal article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 39 (6)
Abstract
Melanoma is a high‐tumor‐mutational‐burden (TMB) cancer, largely driven by ultraviolet‐induced DNA damage. Although TMB predicts response to immune checkpoint inhibitors (ICIs), the genomic factors underlying its variability remain unclear. In addition to canonical DNA‐repair defects such as mismatch repair (MMR) and POLE/POLD1 mutations, alterations in chromatin regulators (CRs) may influence genome stability and mutational load. We analyzed melanoma cohorts from the MSK‐ICI, TCGA, MSK‐Met, DFCI, and UCLA datasets. TMB was compared between CR‐mutant and CR–wild‐type tumors and overall cohorts, along with gene‐level analyses of individual CRs. Associations between the number of CR mutations and TMB were assessed. Overall survival (OS) in ICI‐treated patients was evaluated using Kaplan–Meier and Cox models, with TCGA as a non–ICI‐treated comparator. Across datasets, CR‐mutant melanomas consistently exhibited significantly higher TMB than CR–wild‐type tumors. Several CRs were linked to elevated TMB, comparable to MMR‐ or POLE/POLD1‐mutant tumors. Multiple CR alterations showed a positive linear relationship with TMB. In ICI‐treated cohorts, CR‐mutant tumors had significantly longer OS, while this link was not observed in non–ICI‐treated cases. These findings suggest that CR mutations define a subset of melanomas with high TMB and improved response to ICIs, warranting prospective validation as predictive biomarkers.Keywords
This publication has 12 references indexed in Scilit:
- Breaking Boundaries: Chronic Diseases and the Frontiers of Immune MicroenvironmentsMed Research, 2025
- SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA dataInternational Immunopharmacology, 2020
- Melanoma: What do all the mutations mean?Cancer, 2018
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Genomic and Epigenomic Alterations in CancerThe American Journal of Pathology, 2016
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaCell, 2016
- Oncotarget2016
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Science SignalingScience Signaling, 2013
- Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the hostNature Reviews Cancer, 2013